Expert Interview
Discussing the potential of Zuranolone (SAGE-217) in Major Depressive Disorder before NDA expected in the 2nd Half of 2022
Ticker(s): SAGEInstitution: Baylor
- Professor of Psychiatry and Behavioral Sciences and Brown Foundation Chair of Psychopharmacology of Mood Disorders in the Menninger Department of Psychiatry and Behavioral Sciences at Baylor College of Medicine.
- Currently manages 200 patients with MDD
- Extensive clinical/translational research experience in mood and anxiety disorders; directs a research program focused on early-phase drug discovery and neurobiological research in treatment-resistant mood disorders and PTSD.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
